Product Highlight - MEROMAX IV

17 Dec 2020
Product Highlight - MEROMAX IV
  • Meropenem (Meromax IV) remains the most reliable option against multi-drug resistant gram negative pathogens:
    - ESBL E. coli and Klebsiella pneumonia 95% and 89% susceptible to meropenem1.
    - Pseudomonas aeruginosa 86% susceptibility rate1.
  • Meropenem (Meromax IV) associated with higher survival rate among patients with severe infections due to MDR gram negatives:
    - Lower mortality rate in patients with severe pneumonia, UTI, intra-abdominal
    - infections and sepsis vs. comparator agents2.
    - Superior efficacy against ESBL Klebsiella pneumoniae bacteremia3.
    - Combination of carbapenem and colistin is associated with higher survival against KPC-Klebsiella pneumoniae vs. colistin alone4.

References:
1. 2017 DOH Antimicrobial Resistance Surveillance Program.
2. Clinical Infectious Diseases 2017;64(7):972–80.
3. Clinical Infectious Diseases 2017;64(7):972–80.
4. Clinical Microbiology and Infection 24 (2018) 133e144.


THE CATHAY DRUG CO., INC.
2/F Vernida I Condominium, 120 Amorsolo St., Legaspi Village, Makati City
Website: www.cathaydrug.ph • Fax No.: (+63-2) 818 6739

Related MIMS Drugs